Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study

Area of Science:

• Immunology
• Pharmacology
• Genetics

Background:

• The FAST-2 trial demonstrated icatibant's efficacy for single HAE attack treatments.
• This study assesses repeated icatibant use in HAE patients during the FAST-2 open-label extension.

Purpose of the Study:

• To evaluate the efficacy and safety of repeated icatibant subcutaneous injections for hereditary angioedema attacks.
• To analyze time to symptom relief and attack resolution rates in patients receiving multiple icatibant treatments.

Main Methods:

• Adult patients from the FAST-2 trial received open-label icatibant (30 mg) for HAE attacks.
• Time to symptom relief was recorded for each attack; descriptive and post hoc analyses were performed.
• Safety monitoring included recording adverse events throughout the open-label extension phase.

Main Results:

• Icatibant was administered for 374 HAE attacks (cutaneous, abdominal, laryngeal) in 54 patients.
• Median time to symptom relief for cutaneous/abdominal attacks was 2.0-2.5 hours; for laryngeal attacks, 0.3-4.0 hours.
• 89.8% of attacks resolved with a single icatibant injection; no serious drug-related adverse events were reported.

Conclusions:

• Repeated icatibant treatment is effective for managing hereditary angioedema attacks.
• Icatibant demonstrates a favorable safety profile for long-term use in HAE patients.